Promising combo targets rare lung cancer in new trial
NCT ID NCT07307443
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of anlotinib pills and standard chemotherapy for people with a rare, advanced lung cancer that lacks the SMARCA4 gene. About 28 adults will receive the treatment in 21-day cycles to see how long it keeps the cancer from growing and what side effects occur. The goal is to find a better way to control this hard-to-treat cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.